{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.2","upperLimit":"39.1","value":"19.3"},{"groupId":"OG001","lowerLimit":"5.6","upperLimit":"9.1","value":"7.6"},{"groupId":"OG002","lowerLimit":"1.9","upperLimit":"6.9","value":"4.0"},{"groupId":"OG003","lowerLimit":"8.2","upperLimit":"14.7","value":"10.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"85"},{"groupId":"OG002","value":"41"},{"groupId":"OG003","value":"119"}],"units":"Participants"}],"description":"Progression free survival (PFS) was the time from randomization date to date of first documentation of PD or death due to any cause RECIST version 1.0 (RECIST1.1 for ALK-negative NSCLC cohort 1 and ALK-negative NSCLC cohort 2). PD: \\>=20% increase in the sum of the longest diameter of target lesions taking as references the smallest sum longest diameter recorded since the treatment started, unequivocal progression of existing non-target lesions, or the appearance of 1 or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).","id":"OG000","title":"RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).","id":"OG001","title":"RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).","id":"OG002","title":"RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).","id":"OG003","title":"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"}],"paramType":"MEDIAN","populationDescription":"SA set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1. Here, \"Overall number of participants analyzed\" signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.","reportingStatus":"POSTED","timeFrame":"From randomization until PD or death, whichever occurred first (up to 172 months)","title":"Recommended Phase 2 Dose (RP2D) Cohort: Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Months"}